Market Overview:
The global dry eye syndrome drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of dry eye syndrome, rising awareness about available treatments, and growing demand for novel therapies. By type, the antibiotic drops segment is expected to account for the largest share of the global dry eye syndrome drugs market in 2018. This segment is projected to grow at a CAGR of 6.1% during the forecast period from 2018 to 2030. By application, hospitals are expected to account for the largest share of the global dry eye syndrome drugs market in 2018. This segment is projected grow at a CAGR of 5%.
Product Definition:
Dry Eye Syndrome Drugs are medications used to treat the symptoms of dry eye syndrome. Dry eye syndrome is a condition that can cause your eyes to feel gritty, sandy, or like they have something in them. It can also cause your eyes to be red and irritated. The most common drugs used to treat dry eye syndrome are artificial tears and ointments.
Antibiotic Drops:
Antibiotic drops are used for the treatment of bacterial infections in the human body. The most common type of infection is caused by bacteria such as staphylococcus, streptococcus, and pneumonia. Antibiotics can be administered through oral or injectable routes; however, they are usually given through injections to ensure high efficacy.
Hormone Drops:
Hormone Drops is a formulation of hormones used to treat dry eye syndrome. It is also used in other ocular conditions such as Sjogren's syndrome, end-stage renal disease, and post-surgical states that cause dry eyes. The drug works by stimulating the release of certain natural oils from inside the eye which helps in maintaining lubrication of the eyes.
Application Insights:
Based on the application, the global dry eye syndrome drugs market is segmented into hospitals, clinics, and household use. The household use of these drops accounted for a major share in 2017 owing to rising awareness about DED among consumers. Moreover, increasing consumer health concerns regarding Dry Eye Disease (DED) are expected to fuel demand over the forecast period.
The hospital segment is anticipated to witness lucrative growth during the forecast period due to rising prevalence of diseases such as meibomian gland disorder and blepharitis that necessitate medical treatment with artificial tears or drops for betterment of ocular symptoms. In addition, an increase in healthcare spending by governments across various regions has resulted in growing penetration of these products at lower cost which will further drive their demand over the next few years.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in dry eye syndrome cases, an increase in awareness about Dry Eye Syndrome (DES) treatment options, and availability of well-established healthcare facilities. In addition, introduction of new drugs and increasing R&D activities by major companies are some other factors contributing toward the growth of this regional market.
Asia Pacific is expected to witness lucrative growth over the forecast period due to rising geriatric population prone to various ophthalmic disorders coupled with growing medical tourism industry. Moreover, economic development and improvement in living standards have led many people from middle-income countries like China & India for seeking treatment at high costs in developed nations like U.S., Canada & European Union countries for medical reasons such as advanced surgical procedures or expensive medication available only within these regions will further boost revenue generation capacity during the forecast period 8).
Growth Factors:
- Increasing prevalence of dry eye syndrome (DES) due to various factors such as increasing aging population, rising pollution levels, and growing use of electronic devices
- Growing demand for novel therapies for the treatment of DES
- Rising awareness about DES and its treatment options among patients and healthcare professionals
- Technological advancements in dry eye syndrome drugs market that offer better patient outcomes
- Availability of government funding and initiatives for research on DES
Scope Of The Report
Report Attributes
Report Details
Report Title
Dry Eye Syndrome Drugs Market Research Report
By Type
Antibiotic Drops, Hormone Drops, Artificial Tears
By Application
Hospitals, Clinics, Household Use
By Companies
Allergan, Novartis, Santen, Takeda, Otsuka, Eyegate Pharma, Can-Fite BioPharma, Bausch and Lomb, Auven Therapeutics (Celtic), Bridge Pharma, Cellzome
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Dry Eye Syndrome Drugs Market Report Segments:
The global Dry Eye Syndrome Drugs market is segmented on the basis of:
Types
Antibiotic Drops, Hormone Drops, Artificial Tears
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Household Use
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- Novartis
- Santen
- Takeda
- Otsuka
- Eyegate Pharma
- Can-Fite BioPharma
- Bausch and Lomb
- Auven Therapeutics (Celtic)
- Bridge Pharma
- Cellzome
Highlights of The Dry Eye Syndrome Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotic Drops
- Hormone Drops
- Artificial Tears
- By Application:
- Hospitals
- Clinics
- Household Use
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Dry Eye Syndrome Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Dry eye syndrome drugs are medications used to treat a condition called dry eye. Dry eye syndrome is a common problem that can cause discomfort, blurred vision, and even pain. Some of the most common dry eye syndrome drugs include artificial tears (such as Refresh Tears), ointments (such as Restasis), and pills (such as Timolol).
Some of the key players operating in the dry eye syndrome drugs market are Allergan, Novartis, Santen, Takeda, Otsuka, Eyegate Pharma, Can-Fite BioPharma, Bausch and Lomb, Auven Therapeutics (Celtic), Bridge Pharma, Cellzome.
The dry eye syndrome drugs market is expected to register a CAGR of 5.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Dry Eye Syndrome Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Dry Eye Syndrome Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Dry Eye Syndrome Drugs Market - Supply Chain
4.5. Global Dry Eye Syndrome Drugs Market Forecast
4.5.1. Dry Eye Syndrome Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Dry Eye Syndrome Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Dry Eye Syndrome Drugs Market Absolute $ Opportunity
5. Global Dry Eye Syndrome Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
5.3.1. Antibiotic Drops
5.3.2. Hormone Drops
5.3.3. Artificial Tears
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Dry Eye Syndrome Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Household Use
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Dry Eye Syndrome Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Dry Eye Syndrome Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Dry Eye Syndrome Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Dry Eye Syndrome Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Dry Eye Syndrome Drugs Demand Share Forecast, 2019-2026
9. North America Dry Eye Syndrome Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Household Use
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
9.7.1. Antibiotic Drops
9.7.2. Hormone Drops
9.7.3. Artificial Tears
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Dry Eye Syndrome Drugs Demand Share Forecast, 2019-2026
10. Latin America Dry Eye Syndrome Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Household Use
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
10.7.1. Antibiotic Drops
10.7.2. Hormone Drops
10.7.3. Artificial Tears
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Dry Eye Syndrome Drugs Demand Share Forecast, 2019-2026
11. Europe Dry Eye Syndrome Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Dry Eye Syndrome Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Household Use
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
11.7.1. Antibiotic Drops
11.7.2. Hormone Drops
11.7.3. Artificial Tears
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y--Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Dry Eye Syndrome Drugs Demand Share, 2019-2026
12. Asia Pacific Dry Eye Syndrome Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Dry Eye Syndrome Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Household Use
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
12.7.1. Antibiotic Drops
12.7.2. Hormone Drops
12.7.3. Artificial Tears
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Dry Eye Syndrome Drugs Demand Share, 2019-2026
13. Middle East & Africa Dry Eye Syndrome Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Dry Eye Syndrome Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Dry Eye Syndrome Drugs Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Household Use
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Dry Eye Syndrome Drugs Market Size and Volume Forecast by Type
13.7.1. Antibiotic Drops
13.7.2. Hormone Drops
13.7.3. Artificial Tears
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Dry Eye Syndrome Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Dry Eye Syndrome Drugs Market: Market Share Analysis
14.2. Dry Eye Syndrome Drugs Distributors and Customers
14.3. Dry Eye Syndrome Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Santen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takeda
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Otsuka
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eyegate Pharma
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Can-Fite BioPharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bausch and Lomb
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Auven Therapeutics (Celtic)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bridge Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Cellzome
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
